MC4 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
== Rate of usage == In 2013, 77% of Nigerian women, 52% of Senegalese women, and 25% of Malian women were using lightening products. In 2020, Der Spiegel reported that in Ghana, "When You Are Light-Skinned, You Earn More", and that "[s]ome pregnant women take tablets in the hopes that it will lead their child to be born with fair skin. Some apply bleaching lotion [...] to their babies, in the hopes that it will improve their child's chances." Skin whiteners typically range widely in pricing. Olumide attributes this to the desire to portray whitening as financially accessible to all. These products are marketed to both men and women, though studies indicate that, in Africa, women use skin bleachers more than men do. A study by Lester Davids and his colleagues indicated that nations in Africa present high rates of usage for skin bleachers. Though many products have been banned due to toxic chemical compositions, Davids found that regulating policies are often not strictly enforced. In India, the sales of skin lightening creams in 2012 totaled around 258 tons, and in 2013 sales were about US$300 million. By 2018, the industry for lightening cosmetics in India had achieved a net worth of nearly $180 million and an annual growth rate of 15%. As of 2013, the global market for skin lighteners was projected to reach $19.8 billion by 2018, based on sales growth primarily in Africa, Asia, and the Middle East. In the United Kingdom, many skin whiteners are illegal due to possible adverse effects. Such products are frequently still sold even after shops have been prosecuted.
Severe diabetic hypoglycemia Diabetic ketoacidosis advanced enough to result in unconsciousness from a combination of severe hyperglycemia, dehydration and shock, and exhaustion Hyperosmolar nonketotic coma in which extreme hyperglycemia and dehydration alone are sufficient to cause unconsciousness.
EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid), also known as egtazic acid (INN, USAN), is an aminopolycarboxylic acid, a chelating agent. It is a white solid that is related to the better known EDTA. Compared to EDTA, it has a lower affinity for magnesium, making it more selective for calcium ions. It is useful in buffer solutions that resemble the environment in living cells where calcium ions are usually at least a thousandfold less concentrated than magnesium. The pKa for binding of calcium ions by tetrabasic EGTA is 11.00, but the protonated forms do not significantly contribute to binding, so at pH 7, the apparent pKa becomes 6.91. See Qin et al. for an example of a pKa calculation. EGTA has also been used experimentally for the treatment of animals with cerium poisoning and for the separation of thorium from the mineral monazite. EGTA is used as a compound in elution buffer in the protein purification technique known as tandem affinity purification, in which recombinant fusion proteins are bound to calmodulin beads and eluted out by adding EGTA. EGTA is often employed in dentistry and endodontics for the removal of the smear layer.
Psilocybin is used recreationally, spiritually (as an entheogen), and medically. It is primarily taken orally, but other routes of administration, such as intravenous injection, are sometimes employed by licensed medical researchers using pharmaceutical-grade psilocybin powder designed for injection. Injection should never be attempted by unlicensed people.
== Classification == All enzymes are assigned an Enzyme Commission number based on the chemical reaction they catalyze. An EC number functions to clear up any confusion that arises due to the fact that many enzymes have several different names that can refer to them. Lysine carboxypeptidase's EC number is 3.4.17.3. The first number in an EC number indicates the main class that the enzyme belongs to (the options being oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases). Lysine carboxypeptidase belongs to class 3 which indicates that it is a hydrolase. Hydrolases use water to break apart chemical bonds including, but not limited to, carbon-oxygen, carbon-nitrogen, and carbon-carbon bonds. The second number describes the type of bond that is broken apart in the specific enzyme catalyzed reaction. The "4" places lysine carboxypeptidase in the "peptidase" subclass. This means that this enzyme acts on peptide bonds. The third number (the sub-subclass) gives more information about the catalytic mechanism of the reaction. Lysine carboxypeptidase is in sub-subclass 17: metallocarboxypeptidases. This subclass first defines lysine carboxypeptidase as an exopeptidase (sub-subclasses 11 and 13-19) which means that it only acts on terminal bonds of a polypeptide chain. It is more specifically a carboxypeptidase (sub-subclasses 16-18) which acts on a C-terminus to break off one amino acid. The overall category of metallocarboxypeptidases indicates that it functions using metal ion catalysis.
Sources: en.wikipedia.org
=== Polymer synthesis === SEC can be used as a measure of both the size and the polydispersity of a synthesized polymer, that is, the ability to find the distribution of the sizes of polymer molecules. If standards of a known size are run previously, then a calibration curve can be created to determine the sizes of polymer molecules of interest in the solvent chosen for analysis (often THF). In alternative fashion, techniques such as light scattering and/or viscometry can be used online with SEC to yield absolute molecular weights that do not rely on calibration with standards of known molecular weight. Due to the difference in size of two polymers with identical molecular weights, the absolute determination methods are, in general, more desirable. A typical SEC system can quickly (in about half an hour) give polymer chemists information on the size and polydispersity of the sample. The preparative SEC can be used for polymer fractionation on an analytical scale.
== Signs and symptoms == Migraines typically present as recurrent, mostly one-sided, pulsating headaches, along with heightened sensitivity to light, sound, and other sensory stimuli. The severity of pain, duration of the headache, and frequency of attacks vary. Symptoms may last for hours or days, seriously affecting quality of life. Migraine attacks can be described in terms of four stages or phases, which may not all be experienced.
Hamilton, 1822) (great snakehead) Channa melanoptera (Bleeker, 1855) Channa melanostigma Geetakumari & Vishwanath Waikhom, 2011 Channa melasoma (Bleeker, 1851) (black snakehead) Channa micropeltes (G. Cuvier, 1831) (giant snakehead) Channa ninhbinhensis V. H. Nguyễn, 2011 Channa nox C. G. Zhang, Musikasinthorn & Watanabe, 2002 (night snakehead) Channa orientalis Bloch & J. G. Schneider, 1801 (Ceylon snakehead) Channa ornatipinnis Britz, 2008 Channa panaw Musikasinthorn, 1998 (Panaw snakehead) Channa pardalis Knight, 2016 Channa pleurophthalma (Bleeker, 1851) Channa pomanensis Gurumayum & Tamang, 2016 Channa pseudomarulius (Günther, 1861) Channa pulchra Britz, 2007 Channa punctata (Bloch, 1793) (spotted snakehead) Channa pyrophthalmus Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa quinquefasciata Praveenraj et al., 2018 Channa rakhinica Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa rara Britz, Dahanukar, Anoop & Ali, 2019 Channa royi Praveenraj et al., 2018 (Andaman emerald snakehead) — likely a synonym of C. harcourtbutleri Channa rubora Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa shingon M. Endruweit, 2017) Channa stewartii (Playfair (fr), 1867) (Assamese snakehead) Channa stiktos Lalramliana, Knight, Lalhlimpuia & Singh, 2018 Channa striata (Bloch, 1793) (striped snakehead)
The Crossbell arc consists of two games. They are set in Crossbell, a city-state located between the great powers of Erebonia and Calvard. It follows rookie police investigator Lloyd Bannings and the Special Support Section, consisting of himself, Elie McDowell, Randy Orlando, and Tio Plato, as they protect the city from criminal activity and the geopolitical situation that looms over it. The first game, Trails from Zero, was released in Japan for the PSP in 2010. The second, Trails to Azure, was released in Japan for the PSP in 2011. The duology did not see official English release for over a decade until NIS America took over rights to the series' English localization in 2019. They released Trails from Zero in 2022 and Trails to Azure in 2023 for PlayStation 4, Nintendo Switch, and Windows. Unlike other English language releases in the Trails series, the Crossbell arc lacks English audio and only includes English subtitles with Japanese audio.
Sources: en.wikipedia.org
==== Ireland ==== On May 13, 2025, it was announced that the first Taco Bell restaurant in Ireland would open in the summer of the same year in partnership with Applegreen, with more locations to follow. The first restaurant opened on 16 September 2025 in a new motorway service station off Junction 6 on the M3 in Dunshaughlin, County Meath.
=== Nanoscale and spectroscopy below the diffraction limit === The spatial resolution of FTIR can be further improved below the micrometer scale by integrating it into scanning near-field optical microscopy platform. The corresponding technique is called nano-FTIR and allows for performing broadband spectroscopy on materials in ultra-small quantities (single viruses and protein complexes) and with 10 to 20 nm spatial resolution.
=== Radioactive contamination === RTGs pose a risk of radioactive contamination: if the container holding the fuel leaks, the radioactive material may contaminate the environment. For spacecraft, the main concern is that if an accident were to occur during launch or a subsequent passage of a spacecraft close to Earth, harmful material could be released into the atmosphere; therefore their use in spacecraft and elsewhere has attracted controversy. However, this event is not considered likely with current RTG cask designs. For instance, the environmental impact study for the Cassini–Huygens probe launched in 1997 estimated the probability of contamination accidents at various stages in the mission. The probability of an accident occurring which caused radioactive release from one or more of its three RTGs (or from its 129 radioisotope heater units) during the first 3.5 minutes following launch was estimated at 1 in 1,400; the chances of a release later in the ascent into orbit were 1 in 476; after that the likelihood of an accidental release fell off sharply to less than 1 in a million. If an accident which had the potential to cause contamination occurred during the launch phases (such as the spacecraft failing to reach orbit), the probability of contamination actually being caused by the RTGs was estimated at 1 in 10. The launch was successful and Cassini–Huygens reached Saturn. To minimize the risk of the radioactive material being released, the fuel is stored in individual modular units with their own heat shielding.
Sauvagine is a neuropeptide from the corticotropin-releasing factor (CRF) family of peptides and is orthologous to the mammalian hormone, urocortin 1, and the teleost fish hormone, urotensin 1. It is 40 amino acids in length, and has the sequence XGPPISIDLSLELLRKMIEIEKQEKEKQQAANNRLLLDTI-NH2, with a pyrrolidone carboxylic acid modification at the N-terminal and amidation of the C-terminal isoleucine residue. It was originally isolated from the skin of the frog Phyllomedusa sauvagii. Given its relation to other CRF-related peptides, it exerts similar physiological effects as corticotropin-releasing hormone. Sauvagine belongs to the corticotropin-releasing factor (CRF) family that also includes CRF, urocortin l/urotensin l, urocortin II and urocortin III.
== In plants == The light reactions of photosynthesis generate ATP by the action of chemiosmosis. The photons in sunlight are received by the antenna complex of Photosystem II, which excites electrons to a higher energy level. These electrons travel down an electron transport chain, causing protons to be actively pumped across the thylakoid membrane into the thylakoid lumen. These protons then flow down their electrochemical potential gradient through an enzyme called ATP-synthase, creating ATP by the phosphorylation of ADP to ATP. The electrons from the initial light reaction reach Photosystem I, then are raised to a higher energy level by light energy and then received by an electron acceptor and reduce NADP+ to NADPH. The electrons lost from Photosystem II get replaced by the oxidation of water, which is "split" into protons and oxygen by the oxygen-evolving complex (OEC, also known as WOC, or the water-oxidizing complex). To generate one molecule of diatomic oxygen, 10 photons must be absorbed by Photosystems I and II, four electrons must move through the two photosystems, and 2 NADPH are generated (later used for carbon dioxide fixation in the Calvin Cycle).
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.